Allograft Survival with Iloprost

  • M. L. Foegh
  • J. R. Rowles
  • B. S. Khirabadi
  • P. W. Ramwell
Conference paper


Short-term cardiac allograft survival has improved substantially since the introduction of cyclosporin A (CsA). However, death from coronary atherosclerosis resulting form chronic rejection is now the major problem; clearly CsA does not provide adequate long-term allograft protection and, in addition, possesses a number of undesirable side effects including renal toxicity which is particularly prominent in cardiac transplant patients where some of the patients are now placed on chronic hemodialysis. The combination of prednisone with CsA seems superior to CsA alone in promoting allograft survival. However, treatment with prednisone is also linked to serious short-term side effects including bone necrosis and cataract.


Graft Survival Cardiac Allograft Allograft Survival Cardiac Transplant Patient Cardiac Allograft Survival 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Foegh ML, Alijani MR, Helfrich GB, Ramwell PW (1984) Eicosanoids and organ transplantation. Ann Clin Res 16: 318–323PubMedGoogle Scholar
  2. 2.
    Foegh ML, Alijani MR, Helfrich GB, Khirabadi BS, Goldman MH, Lower RR, Ramwell PW (1985) Thromboxane and leukotrienes in clinical and experimental transplant rejection. Adv Prostaglandin Thromboxane Leukotriene Res, vol 8, 13: 209–217Google Scholar
  3. 3.
    Foegh ML, Khirabadi B, Ramwell PW (1985) Prolongation of experimental cardiac allograft survival with thromboxane-related drugs. Transplantation 40: 124–125PubMedCrossRefGoogle Scholar
  4. 4.
    Foegh ML, Khirabadi BS, Ramwell PW (1985) Prolongation of rat cardiac allograft survival by Ca+ + blockers. Transplantation 40: 211–212PubMedCrossRefGoogle Scholar
  5. 5.
    Jamieson SW, Burton N, Reitz B (1979) Platelets sulfinpyrazone and organ graft rejection. In: McGregor M, Mustard J, Oliver M, Sherry S (1979) Cardiovascular actions of sulfin-pyrazone: basic and clinical research. Symposia Specialist, Miami, pp 329–243Google Scholar
  6. 6.
    Khirabadi BS, Foegh ML, Ramwell PW (1985) Urine immunoreactive thromboxane B2 in rat cardiac allograft rejection. Transplantation 39: 6–8PubMedGoogle Scholar
  7. 7.
    Kort WJ, Bonta IL, Adolfs MJP, Westbrook DL (1982) Synergism of (15S-)-15-methyl-prostaglandin E with either azathioprine or prednisolone on the survival of hearts allografts in rats. Prostaglandin Thromboxane Leukotriene Med 8: 661–664Google Scholar
  8. 8.
    Kreis H, Chekoff N, Droz D et al. (1984) Nonsteroid anti-inflammatory agents as a substitute treatment for steroids in ATGAM treated cadaver kidney recipients. Transplantation 37: 139–145PubMedCrossRefGoogle Scholar
  9. 9.
    Leithner C, Sinzinger H, Schwarz M (1981) Treatment of chronic kidney transplant rejection with prostacyclin — reduction of platelet deposition in the transplant; prolongation of platelet survival and improvement of transplant function. Prostaglandins 22: 783–788PubMedCrossRefGoogle Scholar
  10. 10.
    Leung KH, Michich E (1981) Prostaglandin modulation of development of cell-mediated immunity in culture. Nature 288: 597–599CrossRefGoogle Scholar
  11. 11.
    Ono K, Lindsey ES (1969) Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg 57: 255–259Google Scholar
  12. 12.
    Rappaport RS, Dodge GR (1982) Prostaglandin E inhibits the production of human interleukin 2. J Exp Med 155: 943–948PubMedCrossRefGoogle Scholar
  13. 13.
    Shaw FL (1983) Prolongation of allograft survival by treatment with prostacyclin or aspirin during acute rejection. Transplantation 35: 526–529PubMedCrossRefGoogle Scholar
  14. 14.
    Snyder DS, Beller DI, Unanue ER (1982) Prostaglandins modulate macrophage la expression. Nature 299: 163–165PubMedCrossRefGoogle Scholar
  15. 15.
    Strom TB, Carpenter CB (1983) Prostaglandin as an effective antirejection therapy in rat renal allograft recipients. Transplantation 35: 279–281PubMedCrossRefGoogle Scholar
  16. 16.
    Walker C, Kristensen F, Bettens F, Deweck AL (1983) Lymphokine regulation of activated (G1) lymphocytes I prostaglandin E2-induced inhibition of interleukin 2 production. J Immunol 130: 1770–1773PubMedGoogle Scholar
  17. 17.
    Zao HX, Aziz S, Kasahara K, Billingham ME, Jamieson SW, Stinson EB, Shumway NE (1984) Improved immunosuppression using cyclosporine with 15-methyl prostaglandin E1. Surg Forum 35: 382–384Google Scholar

Copyright information

© Springer-Verlag, Berlin Heidelberg 1987

Authors and Affiliations

  • M. L. Foegh
    • 1
  • J. R. Rowles
    • 1
  • B. S. Khirabadi
    • 1
  • P. W. Ramwell
    • 1
  1. 1.Department of Surgery, Division of Transplantation and Department of Physiology and BiophysicsGeorgetown University Medical CenterUSA

Personalised recommendations